Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Antibody-Drug conjugates
17 evidence topics · 17 sources
Antibody-drug conjugate recommendations in third-line treatment and beyond: ESMO 2026 guideline
Antibody-drug conjugate positioning and sequencing: ABC8 consensus 2026
“In the ADC landscape, DESTINY-Breast06 showed that T-DXd can be an option for patients with HER2-low disease when the decision to initiate cytotoxic therapy is made, now earlier in the treatment sequence, as first-line cytotoxic therapy after progression on endocrine therapy and for whom further endocrine therapy was considered unsuitable, based on a 5.1-month improvement in median PFS over physician's choice chemotherapy (HR: 0.62), OS showed no statistically significant improvement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with HER2 ultra-low disease, the available data remain limited and further evidence is required before a recommendation can be made.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In view of the modest PFS improvement, the absence of mature OS data, the side effect profile, and the availability of other treatment options, Dato-DXd in this setting is not a preferred option at present.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sacituzumab govitecan has moved to a less favored position in this subtype following the negative results of ASCENT-07, which failed to demonstrate superiority over single-agent chemotherapy as first-line cytotoxic therapy in ER+/HER2-negative ABC (median PFS by BICR: 8.3 months in both arms; HR: 0.85)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the absence of validated predictive biomarkers and robust evidence from prospective clinical trials, routine sequencing of ADCs in this setting cannot currently be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan for HER2-low disease: ASCO 2022 rapid recommendation update
Sacituzumab govitecan for hormone receptor-positive disease: ASCO 2023 rapid recommendation update
Comparator regulatory information: trastuzumab deruxtecan
Comparator regulatory information: datopotamab deruxtecan
Comparator regulatory information: sacituzumab govitecan
Trastuzumab deruxtecan after chemotherapy in HER2-low disease: DESTINY-Breast04
“Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor–positive disease and 63 (11.3%) had hormone receptor–negative disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the hormone receptor–positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician’s choice group (hazard ratio for disease progression or death, 0.51; P<0.001) and overall survival was 23.9 months and 17.5 months, respectively (hazard ratio for death, 0.64; P=0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who had received previous treatment with CDK4/6 inhibitors, the median progression-free survival was 10.0 months in the trastuzumab deruxtecan group; without previous CDK4/6 inhibitor treatment, it was 11.7 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjudicated, drug-related interstitial lung disease/pneumonitis occurred in 12.1% of the patients who received trastuzumab deruxtecan; 0.8% had grade 5 events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan in HER2-low disease: DESTINY-Breast04 long-term survival
“For the HR+ cohort, the median OS was 23.9 months (95% CI 21.7–25.2) in the T-DXd arm and 17.6 months (95% CI 15.1–20.2) in the TPC arm (hazard ratio 0.69; 95% CI 0.55–0.87)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade ≥3 TEAEs occurred in 202 patients (54.4%) in the T-DXd arm and in 116 patients (67.4%) in the TPC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs associated with drug discontinuation were investigator-assessed interstitial lung disease (ILD) and/or pneumonitis at 10.2% in the T-DXd arm and peripheral sensory neuropathy at 2.3% in the TPC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan after endocrine therapy in HER2-low or HER2-ultralow disease: DESTINY-Breast06
“Of the 866 patients who underwent randomization, 713 had HER2-low disease, and 153 had HER2-ultralow disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients with HER2-low disease, the median progression-free survival was 13.2 months (95% confidence interval [CI], 11.4 to 15.2) in the trastuzumab deruxtecan group and 8.1 months (95% CI, 7.0 to 9.0) in the chemotherapy group (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75; P<0.001); the results were consistent in the exploratory HER2-ultralow population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events of grade 3 or higher occurred in 52.8% of the patients in the trastuzumab deruxtecan group and in 44.4% of those in the chemotherapy group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjudicated interstitial lung disease or pneumonitis occurred in 49 patients (11.3%; three events were grade 5 in severity) and in 1 patient (0.2%; grade 2), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan by time to progression on first-line CDK4/6 inhibitor: DESTINY-Breast06 subgroup analysis
“Median PFS (95% confidence interval) favored T-DXd versus TPC regardless of time to progression (TTP) on prior first-line endocrine therapy (ET) + cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i): <6 months: 14.0 (11.2-15.9) versus 6.5 (4.2-8.4) months for T-DXd versus TPC; 6-12 months: 13.2 (8.6-16.4) versus 6.9 (4.3-10.4) months; >12 months: 12.9 (9.8-17.1) versus 8.2 (6.9-10.9) months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan after endocrine therapy: FDA approval summary
“Random assignment was 1:1 to T-DXd or investigator's choice of chemotherapy (paclitaxel, nab-paclitaxel, or capecitabine).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The trial also met its key secondary end point, PFS by BICR in the overall population, with a HR of 0.64 (95% CI, 0.54 to 0.76, P < .0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This is the first indication specifying the category of HER2-ultralow expression in breast cancer, and an assay to select patients for this category was approved contemporaneously.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 progression-free survival and safety
“Patients were randomly assigned to Dato-DXd (n = 365) or ICC (n = 367).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS by BICR was 6.9 months (95% CI, 5.7 to 7.4) with Dato-DXd versus 4.9 months (95% CI, 4.2 to 5.5) with ICC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rate of grade ≥3 treatment-related adverse events (TRAEs) with Dato-DXd was lower than ICC (20.8% v 44.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TRAEs (any grade; grade ≥3) were nausea (51.1%; 1.4%) and stomatitis (50%; 6.4%) with Dato-DXd and neutropenia (grouped term, 42.5%; 30.8%) with ICC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 final overall survival
“At data cut-off, median follow-up was 22.8 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OS for the Dato-DXd versus ICC arm did not reach statistical significance (hazard ratio 1.01, 95% confidence interval 0.83-1.22, P = 0.9445).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Use of ADCs (trastuzumab deruxtecan and sacituzumab govitecan) as subsequent therapy was imbalanced: 12.3% in the Dato-DXd arm versus 24.0% in the ICC arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Datopotamab deruxtecan: FDA approval summary
“TB01 demonstrated a 2-month improvement in median PFS for Dato-DXd compared to ICC (6.9 months vs. 4.9 months, respectively; stratified hazard ratio (HR) 0.63 (95% CI: 0.52, 0.76; p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The OS endpoint was not met; at the final analysis (FA) of OS, the median OS was 18.6 months in the Dato-DXd arm and 18.3 months in the ICC arm (HR: 1.01, 95% CI: 0.83, 1.22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most commonly reported adverse reactions (≥20%) with Dato-DXd were stomatitis, nausea, fatigue, alopecia, constipation, dry eye, keratitis, and vomiting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sacituzumab govitecan versus chemotherapy: TROPiCS-02 progression-free survival
“The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sacituzumab govitecan versus chemotherapy: TROPiCS-02 final overall survival
“Overall survival was significantly improved with sacituzumab govitecan versus chemotherapy (median 14·4 months [95% CI 13·0-15·7] vs 11·2 months [10·1-12·7]; hazard ratio [HR] 0·79, 95% CI 0·65-0·96; p=0·020); survival benefit was consistent across Trop-2 expression-level subgroups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ORR was significantly improved with sacituzumab govitecan compared with chemotherapy (57 [21%] patients vs 38 [14%]; odds ratio 1·63 [95% CI 1·03-2·56]; p=0·035)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One fatal adverse event (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote